Oruka Therapeutics
ORKA
25 hedge funds and large institutions have $4.58M invested in Oruka Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more capital invested
Capital invested by funds: $4.17M → $4.58M (+$407K)
4% more funds holding
Funds holding: 24 → 25 (+1)
0.32% more ownership
Funds ownership: 0.97% → 1.29% (+0.32%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
94% less call options, than puts
Call options by funds: $196K | Put options by funds: $3.12M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$1.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$203K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$125K |
| 4 |
SM
SG3 Management
Dorado,
Puerto Rico
|
+$35.3K |
| 5 |
VF
Virtu Financial
New York
|
+$33.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$126K |
| 2 |
B
Bailard
Foster City,
California
|
-$87K |
| 3 |
Millennium Management
New York
|
-$52.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$33.2K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$25K |
ORKA Hedge Fund Activity: Q3 2022 in Review
25 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2022, worth a combined $4.58M — up 9.8% from $4.17M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ORKA positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Newtyn Management, opening a new position worth an estimated $1.18M. The largest seller was Murchinson, exiting entirely with an estimated $126K sold.
- 25 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2022, up from 24 in Q2 2022.
- Funds reported $4.58M of Oruka Therapeutics stock for Q3 2022, up 9.8% quarter-over-quarter.
- 4 funds opened new Oruka Therapeutics positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest Oruka Therapeutics buyer in Q3 2022 was Newtyn Management, an estimated $1.18M added.
- The largest Oruka Therapeutics seller in Q3 2022 was Murchinson, an estimated $126K sold.
Based on aggregated 13F filings for Q3 2022.